Characterization of a Castrate Resistant Prostate Cancer Xenograft Derived from a Patient of West African Ancestry. Characterization of a Castrate Resistant Prostate Cancer Xenograft Derived from a Patient of West African Ancestry

Here we report the establishment and characterization of a Prostate Cancer Patient Derived Explant (PCPDX) from a patient of West African ancestry with metastatic castration resistant disease. The following data represents gene expression in a series of mice carrying this PCPDX and undergoing different treatment courses. Mice were treated for 10 weeks with either Enzalutamide, Cisplatin, or Docetaxel, or appropriate vehicle controls. Overall design: RNA sequencing of gene expression in mice with prostate cancer after standard of care treatment